Brazikumab (AMG 139), a human IgG2 monoclonal antibody, selectively targets the p19 subunit of IL-23 with a dissociation constant (K D) of 0.138 nM, indicating high affinity for human IL-23. It is employed in Crohns disease research [1].
CAS Number:
[1610353-18-8]
* VAT and and shipping costs not included. Errors and price changes excepted